GMED

In a comparison of two medical instruments stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy), GMED emerges as the superior value option. GMED has a forward P/E of 15.81 compared to AXGN's 73.46, a PEG ratio of 1.27 vs 1.42, and a P/B ratio of 2.22 vs 7.47, earning GMED a Value grade of B while AXGN received an F.

Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway.

However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.

The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections.